Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LK101
- Development stage
- Phase 2
- Lead developer
- Likang Life Sciences Holdings
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
LK101 is a personalized neoantigen-targeted cancer vaccine developed by Likang Life Sciences. It is a dendritic cell (DC)-based mRNA vaccine that combines the advantages of mRNA technology and dendritic cell therapy by transducing mRNA encoding patient-specific tumor antigen targets into dendritic cells. This approach aims to elicit specific T cell responses against tumor neoantigens, providing a highly individualized immunotherapy for cancer patients. The vaccine has demonstrated good safety and tolerability in early clinical studies, with activation of anti-tumor immune responses observed in all treated patients. LK101 represents the first personalized neoantigen mRNA vaccine from China to enter clinical trials and receive IND approval from both Chinese and US regulatory authorities[1][2][4][5].
- Other names
- Neoantigen Vaccines
02
Targets
pMHC-I (Peptide–MHC class I complex)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on LK101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LK101.